Search
Cabaletta Bio Inc
CABAAdd to Watchlist
3.310USD
-0.300-8.31%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
368.49MMarket Cap
LossP/E TTM
More Details of Cabaletta Bio Inc Company
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Cabaletta Bio Inc Info
Ticker SymbolCABA
Company nameCabaletta Bio Inc
IPO dateOct 25, 2019
CEONichtberger (Steven)
Number of employees161
Security typeOrdinary Share
Fiscal year-endOct 25
Address2929 Arch Street
CityPHILADELPHIA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19104
Phone12677593100
Websitehttps://www.cabalettabio.com/
Ticker SymbolCABA
IPO dateOct 25, 2019
CEONichtberger (Steven)
Company Executives of Cabaletta Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Steven Nichtberger, M.D.
Dr. Steven Nichtberger, M.D.
Chief Executive Officer, President, Chairman of the Board, Co-Founder
Chief Executive Officer, President, Chairman of the Board, Co-Founder
1.39M
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
22.73K
--
Mr. Michael Gerard, J.D.
Mr. Michael Gerard, J.D.
General Counsel, Secretary
General Counsel, Secretary
6.60K
--
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
President - Science and Technology
President - Science and Technology
--
--
Mr. Mark J. Simon
Mr. Mark J. Simon
Independent Director
Independent Director
--
--
Mr. Anup Marda
Mr. Anup Marda
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine Bollard, M.D.
Dr. Catherine Bollard, M.D.
Independent Director
Independent Director
--
--
Mr. Richard Conover Henriques, Jr.
Mr. Richard Conover Henriques, Jr.
Independent Director
Independent Director
--
--
Dr. David J. Chang, M.D.
Dr. David J. Chang, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Arun Das, M.D.
Dr. Arun Das, M.D.
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Steven Nichtberger, M.D.
Dr. Steven Nichtberger, M.D.
Chief Executive Officer, President, Chairman of the Board, Co-Founder
Chief Executive Officer, President, Chairman of the Board, Co-Founder
1.39M
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
22.73K
--
Mr. Michael Gerard, J.D.
Mr. Michael Gerard, J.D.
General Counsel, Secretary
General Counsel, Secretary
6.60K
--
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
Dr. Gwendolyn Knowlton (Gwen) Binder-Scholl, Ph.D.
President - Science and Technology
President - Science and Technology
--
--
Mr. Mark J. Simon
Mr. Mark J. Simon
Independent Director
Independent Director
--
--
Mr. Anup Marda
Mr. Anup Marda
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, May 11
Updated: Mon, May 11
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
6.48%
Jennison Associates LLC
5.89%
Adage Capital Management, L.P.
5.80%
Millennium Management LLC
3.37%
Cormorant Asset Management, LP
2.89%
Other
75.57%
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
6.48%
Jennison Associates LLC
5.89%
Adage Capital Management, L.P.
5.80%
Millennium Management LLC
3.37%
Cormorant Asset Management, LP
2.89%
Other
75.57%
Shareholder Types
Shareholders
Proportion
Hedge Fund
19.16%
Investment Advisor
17.81%
Investment Advisor/Hedge Fund
10.92%
Sovereign Wealth Fund
1.77%
Research Firm
1.28%
Individual Investor
1.08%
Bank and Trust
0.15%
Venture Capital
0.10%
Pension Fund
0.07%
Other
47.68%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
342
77.78M
51.10%
-21.31M
2025Q4
332
71.53M
101.82%
+2.00M
2025Q3
342
69.53M
105.84%
-3.44M
2025Q2
342
72.97M
65.79%
+36.49M
2025Q1
337
36.48M
122.66%
-25.76M
2024Q4
337
38.65M
120.50%
-4.03M
2024Q3
325
48.73M
125.05%
-4.12M
2024Q2
319
51.66M
131.37%
-2.68M
2024Q1
305
51.55M
117.43%
-5.10M
2023Q4
264
49.06M
116.05%
+7.90M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Investment Management, Inc.
9.86M
8.86%
-502.07K
-4.85%
Dec 31, 2025
Jennison Associates LLC
8.91M
8%
+408.16K
+4.80%
Dec 31, 2025
Adage Capital Management, L.P.
8.83M
7.93%
--
--
Dec 31, 2025
Millennium Management LLC
5.13M
4.61%
+2.39M
+87.47%
Feb 11, 2026
Cormorant Asset Management, LP
4.40M
3.95%
-600.00K
-12.00%
Dec 31, 2025
Bain Capital Life Sciences Investors, LLC
4.26M
3.83%
-5.42M
-55.97%
Dec 31, 2025
Norges Bank Investment Management (NBIM)
2.69M
2.42%
+2.69M
--
Dec 31, 2025
Two Sigma Investments, LP
2.58M
2.32%
+1.78M
+221.62%
Dec 31, 2025
Superstring Capital Management LP
2.25M
2.02%
+709.02K
+45.91%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.06%
Avantis US Small Cap Equity ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Humankind US Stock ETF
0%
ProShares UltraPro Russell2000
0%
Optimize Strategy Index ETF
0%
Alger 35 ETF
0%
iShares Russell 2000 Value ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.06%
Avantis US Small Cap Equity ETF
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Humankind US Stock ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Optimize Strategy Index ETF
Proportion0%
Alger 35 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
